What We Do?
20

Articles

30

Reports

50

Posters

160

Researches

ECONiX converts information to knowledge with structured researches and precise analytics

Phase 1
Phase 2
Phase 3
Phase 4
  • Define broad strategy
  • Define value and communication story
  • Differentiation of pricing strategy
  • Conduct early payer engagement studies
  • Medical needs gap analysis
  • Finalize launch timelines and pricing strategy
  • Implement the value dossiers and health economics model by local affiliates
  • Prepare dossiers and apply for pricing and reimbursement
  • Conduct projects for societal support

Market Search & Business Development

    • KOL Mapping
    • Environment mapping
    • Competitor mapping
    • Business planning
    • Horizen screening

Medical Affairs and Biostatistics

    • Advisory board support
    • Medical marketing support
    • Medical writing & publications
    • Biostatistics analysis and reporting
    • Value communications

HEOR & Market Access & Health Policy

    • Stakeholder mapping
    • Define the value of product
    • Conduct cost-effectiveness & budget impact analysis and cost-of illness analysis with real world data or modeling
    • Prepare market access and health policy strategy
    • Support to implement the market access and health policy strategy

The market access strategy needs to start as early as early access programs!

Review:

  • Product profile
  • Competitive environment
  • Market dynamics
  • Pricing & reimbursement of competitors
  • Target Population

Secondary research:

  • Literature search
  • Treatment guidelines

Market Access Processes:

  • P&R process
  • HTA Review
  • Mapping and understanding of country-specific pricing and reimbursement processes requirements
  • MA current trends in each country
  • Define critical success factors to achieve successful market access

Payer research: 

  • Interview guide
  • KOLs & payers interviews
  • Analysis & consolidation of findings

Assessment:

  • Achievable / optimal price per country
  • Possible scenarios
  • Launch sequence
  • International price referencing
  • National price referencing

Value dossier preparation including:

  • Systematic literature researches, meta analysis, etc.
  • Modeling, cost-effectiveness, cost-utility analysis
  • Budget impact analysis

Recommendations:

  • Price strategy
  • Actions & data to support pricing & market access
  • Poster & article preparation
  • Application assessment
Publications

Articles

  • Cost Analysis of Management of Cardiovascular Disease Comorbidities in Turkey
  • Analysis of Gene and Cell Therapies Policies in European Countries
  • Cost Effectiveness of Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients for TTR and CHADS2 Score in Turkey
  • Analysis of Psychotropic Medications Prescriptions in Turkey
  • Incidence of Unlicensed and Off-Label Prescription in the Treatment of Urological Cancers in Turkey: Assessment of Legislative and Regulatory Policy

Posters

  • PGI25 Clinic and Economic Analysis for Diagnisis and Treatment of Difficult Bile Duct Stones with Singel Operator Cholangiiscopy in Turkey
  • PCV48 Cost Effectiveness of Rivaroxaban in Coronary Artery Disease and/or Peripheral Artery Disease for 5 Differen Patient SUB-GROUPS in Turkey
  • PMS32 Cost Minimization Analysis of Zentius for the Treatment of Vitamin D and Calcium Deficiency in Turkey
  • PCN301 Patient Access to Personalized Oncology Medicines in TURKEY
  • PNS188 Analysis of Market Access Agreements in Turkey
  • PCV75 Cost Analysis of Complications with Coronary Artery Disease or Peripheral Artery Disease in Turkey
  • PND32 Cost-Efectiveness and Budget Impact of Vagus Nerve Stimulation with Aspire sr Model 106 Compared to Anti-Epileptic Drugs in a Subgroup of Patients with Drug Resistant Epilepsy in Public Setting in Turkey
  • PSY33 HTA Review of Decisions for Products Indicated in the Treatment of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (N) in UK, Germany, France, Italy, Spain, Canada and Turkey
  • PNS159 Pharmacoeconomics and Health Outcome Studies in Turkey: ISPOR Database Search
  • PBI42 Analysis of Gene and Cell Therapies Policies in European Countrie
  • PCV61 Cost Effectiveness of Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients for TTR and CHADS2 Score in Turkey
  • PCV94 Cost Effectiveness of Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients for TTR and CHADS2 Score in Lithuania
  • PRO75 Patient Access to Orphan Medicines in Turkey

Reports

Articles

  • Sosyoekonomik Durumun Diyabet ile İlişkisi ve Diyabete Etkisinin İncelenmesi
  • COVID-19 Tanı Yöntemleri̇ne Bakış: Hızlı Si̇stemati̇k İnceleme
  • Health Policies About Gene & Cell Therapies in France, Germany, Italy, United Kingdom, Spain, Portugal and Turkey
  • A Market Research Of Obesity And Bariatric Surgery In Turkey And Tunisia
  • Efficacy and Safety of PD-1/PD-l1 inhibitors Used in the Treatment of Patients with Advanced and Metastatic Melanoma-A Systematic Review and Network Meta-Analysis

Posters

  • PIN54 Economic IMPACT of Use of Preventive 1000 MG/Day Vitamin C in FLU Season Depending on a Decision Tree MODEL for Turkey
  • PIN27 Economic IMPACT of Use of Preventive 1000 MG/Day Vitamin C in FLU Season Depending on Markov a MODEL for Turkey
  • PIN53 Cost of Productivity Loss of Common Cold and FLU in Turkey
  • PCN198 Access Status of Oncology Medicines Depending on Genetic Profiling in Turkey
  • PSS6 Loss of Productivity Due to Visual Impairment in Turkey
  • PRO49 Cost-Consequences Analysis of Current and Upcoming Hemophilia-a Treatments in Turkey
  • PNS97 The TREND of Health Economics and Outcome Studies from Turkey Published in Ispor
  • PNS83 Analysis of Market Access Agreements in Turkey
  • PMH28 Antidepressant Consumption in Turkey between 2015-2017: Panel DATA Analysis
  • PIN56 Cost of COVID-19 Patients Treatment in Turkey
  • PIN8 A MODEL for Estimation of Possible COVID-19 Patient Numbers in Turkey
  • PMU15 Comparison of Clinical and Economical Outcomes of Alternative Imaging Methods in Turkey
  • PCV26 COMPARISON OF CLINICAL AND ECONOMIC OUTCOMES OF MAGNETIC RESONANCE IMAGING WITH GADOBUTROL, GADOTERIC ACID AND PERIPHERAL ANGIOGRAPHY IN DIAGNOSIS OF VASCULAR DISEASES
  • PDB55 Analysis of Obesity and Bariatric Surgery for Turkey
  • PCN155 Comparison of Clinical and Economic Outcomes of Gadoxetic-Acid and Extracellular Contrast Agent Magnetic Resonance Imaging and Contrast Computed Tomography in the Diagnosis of Liver Metastasis

Reports

Articles

  • Cost Effectiveness Analysis of the Triclip™ Transcatheter Tricuspid Valve Repair System in Patients with Tricuspid Regurgitation (Yayın aşamasında)
  • Analysis of Patient Access to Orphan Drugs in Turkey
  • Determining the Impact of Vitamin C Use with the Common Cold on Loss of Labour and Medical Treatment Costs for Turkey
  • Changes in Catastrophic Health Expenditures Depending on Health Policies in Turkey
  • Accelerated Globalization and Its Impact to the World’s Health Care Achievement

Reports

Articles

  • Antidepressant use in Turkey by provinces: panel data analysis.
  • Cost-Effectiveness Analysis of the Triclip™ Transcatheter Tricuspid Valve Repair System in Patients with Tricuspid Regurgitation.
  • TÜRKİYE’DE KOLOREKTAL KANSER TARAMALARININ MALİYET ETKİLİLİK ANALİZİ.
  • Gene and Cell Therapies Overview Under The Light of Health Economics.

Reports

ECONiX 2022 Yılı İlaç Dönemsel Sabit Avro Kuru Beklenti Anketi
2021 Yılı Türkiye’de İlaçların Uluslararası Referans Fiyatlandırma Analizi
2021 Yılı Türkiye’de Kamu Sağlık Sigortası Harcamalarının Değerlendirilmesi
2010 – 2021 Yılları Arası Türkiye İlaç Geri Çekme Analizi
GERÇEK YAŞAM VERİLERİ İLE TÜRKİYE DÜŞÜK EJEKSİYON FRAKSİYONLU KALP YETERSİZLİĞİ HASTALIK MALİYETİ
HEART FAILURE WITH REDUCED EJECTION FRACTION COST IN TURKEY WITH REAL WORLD DATA
POSSIBLE IMPACT OF BIDEN ADMINISTRATION`S PHARMACEUTICAL POLICIES ON TURKEY
Türkiye Yüksek Öğretim Kurumu Verileri İle Tıp Fakülteleri İnceleme Raporu
2007-2021 Yılları Arasında Türkiye İlaç Pazarında Yaşanan Değişimlerin İncelenmesi
HIV / AIDS Dünya ve Türkiye Değerlendirmesi
SAĞLIK SEKTÖRÜNDE ÜRETİM MALİYETLERİNİ ETKİLEYEN MAL VE HİZMET FİYATLARINDA YAŞANAN DEĞİŞİMLERİN İNCELENMESİ